[Retracted] A Systematic Review and Meta-Analysis of Therapeutic Efficacy and Safety of Alirocumab and Evolocumab on Familial Hypercholesterolemia

Figure 3

Appraisal of the risk of bias of the included studies: (a) any adverse events; (b) serious adverse events; (c) leading to treatment discontinuation; (d) adjudicated cardiovascular events; (e) nervous system disorders; (f) creatine kinase (); (g) headache; (h) nasopharyngitis; (i) abnormal liver function risk (AST/); (j) injection site reactions.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)